Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Malignant Progression of Meningiomas: Occurrence, Outcomes, and Underpinning Factors.

World neurosurgery·2026

Same author

Dynamic 3D Modeling and Preoperative Surgical Planning for Vascular Eagle Syndrome: 2-Dimensional Operative Video.

Operative neurosurgery (Hagerstown, Md.)·2026

Same author

From barrier to bridge: a scoping review on the methods, clinical efficacy, and safety of blood-brain barrier disruption in treating high-grade glioma.

Journal of neuro-oncology·2026

Same author

Clinical presentation, imaging features and surgical outcomes of pineal region epidermoid cysts: A scoping review.

Neurosurgical review·2026

Same author

Clinical Presentation and Management of Dural Arteriovenous Fistulas Fed by the Artery of Davidoff and Schechter: Scoping Review and Case Illustration.

Operative neurosurgery (Hagerstown, Md.)·2026

Same author

Accessory Foramina Presence Significantly Narrows the Jugular Foramen: Anatomical Study with Potential Neurosurgical Significance.

Journal of neurological surgery. Part B, Skull base·2026

Same journal

Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine.

Expert review of anticancer therapy·2026

Same journal

Barriers to the use of brachytherapy for treatment of cervical cancer and prostate cancer in low- and middle-income countries.

Expert review of anticancer therapy·2026

Same journal

The dual role of Schlafen11 in brain tumors: Jekyll and Hyde.

Expert review of anticancer therapy·2026

Same journal

Central nervous system-related permanent consequences in long-term survivors of pediatric Langerhans cell histiocytosis: a clinical overview and monitoring strategies.

Expert review of anticancer therapy·2026

Same journal

RTsDEN: reverse task attention enabled deep learning model for lung cancer detection using computed tomography.

Expert review of anticancer therapy·2026

Same journal

The potential impact of glucagon-like peptide 1 receptor agonists for the treatment of endometrial carcinoma.

Expert review of anticancer therapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Sep 2, 2025

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Emerging immune-based technologies for high-grade gliomas.

Alice Giotta Lucifero¹, Sabino Luzzi^1,2

¹Neurosurgery Unit, Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.

Expert Review of Anticancer Therapy

|August 4, 2022

Summary

This summary is machine-generated.

Emerging immunotherapies show promise for high-grade gliomas (HGGs) treatment by targeting tumor immunity. Research explores novel strategies to overcome brain tumor immune evasion and improve patient survival.

Keywords:

CAR T glioblastoma high-grade glioma immunotherapy monoclonal antibodies oncolytic virus peptide vaccine tumor microenvironment

More Related Videos

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

Related Experiment Videos

Last Updated: Sep 2, 2025

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

Area of Science:

Neuro-oncology
Immunology
Cancer Therapy

Background:

High-grade gliomas (HGGs) present complex treatment challenges due to genetic heterogeneity and therapeutic resistance.
Understanding immune evasion mechanisms in the tumor microenvironment is crucial for developing effective therapies.
Glioblastoma's genetic landscape significantly impacts tumor growth and response to treatment.

Purpose of the Study:

To review emerging immunotherapies for high-grade gliomas.
To discuss immunosuppressive mechanisms within the glioma tumor microenvironment.
To explore future perspectives for overcoming immune barriers in glioma treatment.

Main Methods:

Extensive literature review of PubMed/Medline and ClinicalTrials.gov.
Selection of highly relevant English articles published within the last 20 years.
Summarization of immunotherapy data from preclinical and clinical trials.

Main Results:

Immunotherapies for HGGs demonstrate noteworthy efficacy and safety.
Monoclonal antibodies are approved for second-line treatment.
Peptide vaccines, viral gene strategies, and adoptive cell therapies enhance antitumor immunity.

Conclusions:

Novel immune-based treatment algorithms are being developed to improve overall survival for HGG patients.
Advancements in drug delivery routes and continuous refinement of therapies are anticipated.
Malignant brain tumor-treating fields represent an evolving area with future potential.